Oncology Institute Q1 revenue $76M (+38% YoY) but net loss $30M, EBITDA loss widens

Oncology Institute, Inc.

2023-Q1 EPS reported -$0.33 revenue$76,192,000

Revenue of $76M, up 38.1% YoY; gross profit $14M (18.5% margin, down from 22.3%).
Net loss of $30M ($0.33 diluted loss) vs net income of $19.3M ($0.22 EPS) in Q1 2022.
Adjusted EBITDA loss of $7.9M vs loss of $5.2M in prior year; cash of $114M.
Patient visits up 17% YoY; oral drugs dispensed up 34% YoY.
New value-based contracts in CA and TX; Florida gainshare shows >50% referral capture and >30% cost savings; Q3 guidance reaffirmed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Oncology Institute, Inc. reported three months ended March 31, 2023 results: revenue $76 million, net income Net loss of $30.0 million, EPS $(0.33). Guidance reaffirmed.

Period: three months ended March 31, 2023
Revenue: $76 million
Net income: Net loss of $30.0 million
EPS: $(0.33)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

savings • Patient visits up 17% compared to Q1 2022 • Oral drugs dispensed increased 34% compared to Q1 2022 First Quarter 2023 Financial Highlights • Consolidated revenue of $76 million, an increase of 38.1% from $55 million compared to the prior year quarter • Gross profit of $14 million, an increase of 14.4% compared to the prior year quarter, and gross margin

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-017224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.